Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody

BACKGROUND: Limitations to current therapies for treating non-Hodgkin B cell lymphoma include relapse, toxicity and high cost. Thus, there remains a need for novel therapies. Oncolytic viral (OV) therapy has become a promising cancer immunotherapy because of its potential effectiveness, specificity...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Minjun, Scherwitzl, Iris, Opp, Silvana, Tsirigos, Aristotelis, Meruelo, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6632218/
https://www.ncbi.nlm.nih.gov/pubmed/31307539
http://dx.doi.org/10.1186/s40425-019-0664-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6632218/
https://www.ncbi.nlm.nih.gov/pubmed/31307539
http://dx.doi.org/10.1186/s40425-019-0664-3

Ejemplares similares